Recently, it has become understood that unaltered TP53 and mutated TP53 within tumor cells can be therapeutically targeted, which has led to the use of novel therapies like, APR-456 which has reported to restore transcriptional activity in mutant p53 or unfolded WT p53, leading to apoptosis or the promising result of anti CD47monoclonal antibody magrolimab in TP53 mutated AML. The gene discussed is TP53; the disease is acute myeloid leukemia.